language_icon
EN
HI

Shilpa Medicare Share price

SHILPAMED

315.8

8.80 (-2.71%)
NSE
BSE
Last updated on 19 Mar, 2026 | 14:30 IST
Today's High

325.55

Today's Low

314.25

52 Week Low

259.50

52 Week High

500.00

Zero AMC

Free Demat with Zero AMC*

Open a Free Demat Account
+ Free 1st Year AMC

Shilpa Medicare Chart

Shilpa Medicare Share Key Metrics

Volume
1.90 L
Market Cap
6348.59 CR
LTQ@LTP
1@315.80
ATP
319.37
Var Margin
19.97 %
Circuit Range
259.7-389.5
Delivery %
53.07 %
Value
6.07 CR
ASM/GSM
No
Market Lot
1

Summary

At 19 Mar, 2026 | 14:30, Shilpa Medicare share price stands at ₹315.8, showing a 8.80% -2.71 for the day. The stock’s intraday movement has stayed between ₹314.25 and ₹325.55, while on a 52-week basis it has fluctuated from ₹259.50 to ₹500.00.
In terms of trading activity, Shilpa Medicare has recorded a volume of 190043 shares, with a market capitalisation of ₹195581816. The stock’s Average Traded Price (ATP) stands at ₹31937, while the Last Traded Quantity at Last Traded Price (LTQ@LTP) is 1,31580. The stock operates within a circuit range of ₹259.7-389.5, with a Value of ₹6.07 CR. The Delivery Percentage for the day is 53.07%. Additionally, Shilpa Medicare currently falls under the No framework, and trades with a market lot size of 1.

Shilpa Medicare Fundamentals

View More
P/E Ratio

41.38

P/B Ratio

2.49

Div. Yield

0.16

Sector P/E

59.11

Sector P/B

2.64

Sec. Div. Yield

0.59

Shilpa Medicare Resistance and Support

Pivot 323.82

Resistance

First Resistance

329.49

Second Resistance

334.37

Third Resistance

340.04

Support

First Support

318.94

Second Support

313.27

Third Support

308.39

Shilpa Medicare Futures & Options

Data Not Found

Shilpa Medicare Shareholding Pattern

View More
  • 2016-17
  • 2018-19
  • 2019-20
  • 2020-21
  • 2021-22
  • 2022-23
  • 2023-24
  • 2024-25
  • 2025-26
Total Promoters
Segment
Percent

Total Promoters

40.13%

Mutual Fund

5.2%

Insurance

1.79%

Foreign Institutional Investors

10.97%

Domestic Institutional Investors

1.34%

Retail

40.56%

Others

0.01%

Total Promoters
MAR '25
44.23%
JUN '25
44.23%
SEP '25
44.23%
DEC '25
40.13%

Shilpa Medicare Corporate Actions

DateAgenda
2026-02-06Quarterly Results
2025-11-13Quarterly Results
2025-05-26Audited Results & Final Dividend
2025-02-10Quarterly Results

Shilpa Medicare News

Shilpa Medicare Ltd - 530549 - Announcement under Regulation 30 (LODR)-Scheme of Arrangement

Shilpa Medicare received NCLT approval for the amalgamation scheme of its wholly-owned subsidiary, Shilpa Therapeutics Private Limited. The scheme, effective from April 1, 2025, ensures employees are absorbed on favourable terms and addresses all regulatory observations.
Mar 17 2026 16:03:00

Shilpa Medicare Ltd - 530549 - Announcement under Regulation 30 (LODR)-Scheme of Arrangement

NCLT approves amalgamation of Shilpa Therapeutics Private Limited, a wholly-owned subsidiary, with Shilpa Medicare Limited. The scheme is effective from April 1, 2025, simplifying the corporate structure and absorbing all employees.
Mar 05 2026 19:03:00
Read More

About Shilpa Medicare

NSE : 17752  
BSE : 530549  
ISIN : INE790G01031  

Shilpa Antibiotics Ltd was incorporated as a PrivateLimited Company in November 1987. The commercialproduction of the Company had started in November 1989.The Company was initially producing Trimethoprim IP/BP anantibiotic bulk drug. The technology for the bulk drug wasdeveloped in house. During the first year of its operationthe Company had installed production facilities tomanufacture Trimethoprim Apart from selling on its own theCompany had also started manufacturing the product forother reputed Companies like Eskayef Limited Bombay Drugsand Pharmas Limited Bombay Drug House Ltd. US VitaminsLtd Sandoz India Ltd etc for their export commitments.During 1992 the Company had installed productionfacilities for manufacture of Sodium Methoxide. Thetechnology for the same had also been developed in house.During the same year the Company secured Export orders fromStellar Exports Limited Glaxo Limited and Deepak NitriteLimited for Trimethoprim. Since then the company hasstarted exporting on its own. The Company thus startedmanufacturing for both export and domestic markets since1992. It has obtained World Health Organisation-GoodManufacturing Practices (GMP) Certificate. It has alsobeen exporting its products to hard currency areas.The Company now proposes to embark upon an expansionproject which involves the addition of one more bulk drugto its existing product range viz; Norfloxcin and expansionof the production capacity of the existing product of theCompany viz; Sodium Methoxide and Trimethoprim. TheCompany also proposes to manufacture 1-MethylAmino-1-Methyl Thio-2-Nitro Ethane a drug intermediateused in the manufacture of Ranitidine an anti-ulcer drug.To raise the necessary resources to finance the expansionproject of the Company the Company was converted into aPublic Limited Company in November 1993.As the company''s sales are comparatively more in theSeptember to March period therefore to reduce theadministrative bottlenecks in the timely preparation ofannual results the company changed its accounting yearfrom March end to September end.Objects of the CompanyThe relevant objects of the company as set out in thememorandum of association of the company are :Main Objects1. To carry on in India or elsewhere the industry trade orbusiness of manufacturers Traders Dealers AgentsSuppliers Licensors Licensees Loan Licenses ImportersExporters Consultants Discoverers Inventors andProducers of Drugs Bulk Drugs PharmaceuticalsPharmaceutical Formulations Alcohol Bended LaboratoryPreparations and general medicinal preparation and ortheir by-products and packing and re-packing of the above.

Read More

Shilpa Medicare Management

NamePosition
Mr. Omprakash Inani Chairman
Mr. Vishnukant C Bhutada Managing Director
View More

Shilpa Medicare FAQs

The Buying Price of Shilpa Medicare share is 315.8 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.

To buy Shilpa Medicare stocks, log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Shilpa Medicare, choose your preferred order type, and place the trade.

The Price-to-earnings (P/E) ratio of Shilpa Medicare shares is 41.38. You can compare it with the sector average for relative valuation.

The Price to Book (P/B) ratio Shilpa Medicare shares is 2.49. Useful to assess the stock's value relative to its book value.

To assess Shilpa Medicare’s valuation compare Sector P/E, P/B which are 59.11 & 2.64 with sector averages, along with growth rates and financial metrics.

The Market Cap of Shilpa Medicare is 6348.59 CR. It indicates the company's size category and trading liquidity.

The 52 week high and low prices of Shilpa Medicare share price is 500.00 & 259.50. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.

Shilpa Medicare belongs to the Healthcare sector.

Invest with Zero-Cost Demat Account

Zero AMC for First Year
Free Research Calls
₹ 0 Trade & Call Fee
Zero-Cost